User Fee Conference Cmte. Could Be Relatively Messy After Clean Floor Votes
House and Senate avoided some contentious issues when passing their user fee bills, leaving them to an informal conference committee to work out, ideally before the end of June.
You may also be interested in...
The agency is convening the Drug Safety and Risk Management Advisory Committee Oct. 29-30 to discuss whether combination hydrocodone products should face further restrictions.
The agency distinguishes the lidocaine pain patch from topical dermatological drugs intended to treat skin diseases in rejecting Endo’s call that ANDA sponsors demonstrate bioequivalence through clinical trials, rather than merely pharmacokinetic studies.
The North Carolina Republican spends more than two hours talking about the user fee bill and other issues in an apparent effort to delay a final vote, but the Senate easily passes it.